Agios Pharmaceuticals (AGIO) Given News Sentiment Score of 0.19

News stories about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.4823791328081 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Get Agios Pharmaceuticals alerts: Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)’s Value in Focus as VC2 Touches 94 (bedfordnewsjournal.com) Earnings Spotlight on Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) (mtlnewsjournal.com) Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal (seekingalpha.com) AGIOS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com) BRIEF-Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop … (sg.news.yahoo.com)

AGIO has been the topic of several research analyst reports. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. BidaskClub lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 26th. Credit Suisse Group set a $95.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 11th. Piper Jaffray Companies started coverage on Agios Pharmaceuticals in a research report on Wednesday, May 30th. They set an “overweight” rating and a $125.00 price target on the stock. Finally, Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 17th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $95.55.

Agios Pharmaceuticals stock traded down $0.91 during midday trading on Wednesday, hitting $84.61. 271,886 shares of the company were exchanged, compared to its average volume of 324,958. Agios Pharmaceuticals has a fifty-two week low of $51.29 and a fifty-two week high of $99.82. The firm has a market capitalization of $4.93 billion, a PE ratio of -12.53 and a beta of 2.01.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The business had revenue of $8.80 million during the quarter, compared to the consensus estimate of $11.93 million. During the same period in the previous year, the business posted ($1.56) EPS. Agios Pharmaceuticals’s revenue was down 16.2% compared to the same quarter last year. sell-side analysts anticipate that Agios Pharmaceuticals will post -6.41 earnings per share for the current year.

In other Agios Pharmaceuticals news, insider Scott Biller sold 3,000 shares of the stock in a transaction dated Thursday, April 5th. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the completion of the sale, the insider now owns 60,196 shares in the company, valued at approximately $4,526,739.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO David P. Schenkein sold 13,000 shares of the stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $83.04, for a total transaction of $1,079,520.00. Following the completion of the sale, the chief executive officer now owns 13,000 shares of the company’s stock, valued at approximately $1,079,520. The disclosure for this sale can be found here. In the last ninety days, insiders sold 162,277 shares of company stock worth $14,583,250. 3.02% of the stock is owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.